Schizophrenia: elevated mRNA for calcium-calmodulin-dependent protein kinase IIbeta in frontal cortex

Brain Res Mol Brain Res. 2000 Oct 20;82(1-2):95-100. doi: 10.1016/s0169-328x(00)00188-1.

Abstract

Because amphetamine releases two to three times more dopamine in schizophrenia patients than in control subjects, and because calcium-calmodulin-dependent protein kinase II has a key role in the enhanced action of amphetamine-induced dopamine release in rats, the synaptic content of calcium-calmodulin-dependent protein kinase IIbeta mRNA was measured (by quantitative competitive RT-PCR; reverse transcriptase-polymerase chain reaction) in seven frontal cerebral cortices of post-mortem brains from patients who had schizophrenia and in seven control tissues. The results indicate that the mRNA of this kinase is elevated in the schizophrenia frontal cortex.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Base Sequence
  • Cyclic AMP-Dependent Protein Kinase RIIbeta Subunit
  • Cyclic AMP-Dependent Protein Kinases / genetics*
  • Female
  • Frontal Lobe / metabolism*
  • Gene Expression Regulation, Enzymologic*
  • Humans
  • Male
  • Molecular Sequence Data
  • RNA, Messenger / genetics
  • Reference Values
  • Reverse Transcriptase Polymerase Chain Reaction
  • Schizophrenia / enzymology*
  • Schizophrenia / genetics*
  • Transcription, Genetic*

Substances

  • Cyclic AMP-Dependent Protein Kinase RIIbeta Subunit
  • PRKAR2B protein, human
  • RNA, Messenger
  • Cyclic AMP-Dependent Protein Kinases